

# STK11 gene

## Associated Syndrome Name: Peutz-Jeghers syndrome (PJS)

### STK11 Summary Cancer Risk Table

CANCER	GENETIC CANCER RISK
Breast	High Risk
Colorectal	High Risk
Endometrial	High Risk
Gastric	High Risk
Lung	High Risk
Other	High Risk
Ovarian	High Risk
Pancreatic	High Risk
Other	Elevated Risk

### STK11 gene Overview

Peutz-Jeghers syndrome (PJS) <sup>1, 2, 3, 4, 5, 6, 7</sup>

- Individuals with mutations in the *STK11* gene have a condition called Peutz-Jeghers syndrome (PJS).
- Women with PJS have a risk for breast cancer that is significantly increased over the 12.5% lifetime risk for women in the general population of the United States. Individuals with PJS have high risks for a variety of other cancers, including colorectal, endometrial, gastric, pancreatic, small bowel, cervical and lung cancers. These cancers are often diagnosed at relatively young ages.
- The cervical cancer associated with PJS, adenoma malignum, which is also known as minimal deviation adenocarcinoma (MDA), may be difficult to diagnose.
- Women with PJS have an increased risk for ovarian neoplasms, including adenocarcinomas. However, sex cord tumors are the most common ovarian tumor found in these patients.
- Males with PJS have an increased risk for testicular tumors, particularly large cell calcifying Sertoli cell tumors (LCCSCT). These tumors have a low risk for malignancy, but if left untreated may lead to feminizing changes, advanced skeletal age and short stature.
- Patients with PJS are likely to develop hamartomatous gastrointestinal polyps with a distinctive Peutz-Jeghers histology. The most common location of these polyps is the small bowel, but they may also be found in the stomach, colon and nasal passages. Polyps may require treatment due to bleeding with subsequent anemia, recurrent obstruction and/or intussusception.
- Patients with PJS are likely to develop pigmented spots around the mouth, eyes, nostrils, anus and on the fingers during childhood. These spots are usually present by age 5 and often fade during puberty and adulthood.
- Although there are high risks for cancer and other medical problems in patients with PJS, these risks can be reduced with appropriate medical management. Guidelines from the National Comprehensive Cancer Network (NCCN), American Association for Cancer Research (AACR), and US Multi-Society Task Force (USMSTF) are listed below. Due to the complexity of the condition it is recommended that patients with *STK11* mutations and a diagnosis of PJS be managed by a multidisciplinary team with experience in the prevention and treatment of the complications associated with this condition.

### STK11 gene Cancer Risk Table

CANCER TYPE	AGE RANGE	CANCER RISK	RISK FOR GENERAL POPULATION
Colorectal	To age 70 <sup>1, 3, 8</sup>	39%	1.8%
Pancreatic	To age 70 <sup>1, 3, 8</sup>	11%-36%	0.6%
Female Breast	To age 70 <sup>1, 3, 8</sup>	32%-54%	7.6%

CANCER TYPE	AGE RANGE	CANCER RISK	RISK FOR GENERAL POPULATION
Gastric	To age 70 <sup>1, 3, 8</sup>	29%	0.3%
Small Bowel	To age 70 <sup>1, 3, 8</sup>	13%	0.1%
Ovarian	To age 70 <sup>1, 8</sup>	18%-21%	0.6%
Lung	To age 70 <sup>1, 3, 8</sup>	7%-17%	1.9%
Cervical	To age 70 <sup>1, 3, 8</sup>	10%	0.5%
Endometrial	To age 70 <sup>1, 3, 8</sup>	9%	1.9%
Testicular	To age 70 <sup>3, 8</sup>	Elevated risk	0.4%

## STK11 Cancer Risk Management Table

The overview of medical management options provided is a summary of professional society guidelines. The most recent version of each guideline should be consulted for more detailed and up-to-date information before developing a treatment plan for a particular patient.

This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient's personal medical history, surgeries and other treatments.

CANCER TYPE	PROCEDURE	AGE TO BEGIN	FREQUENCY (UNLESS OTHERWISE INDICATED BY FINDINGS)
Colorectal	Colonoscopy <sup>1, 6, 7</sup>	Baseline at age 8 to 10 years, or earlier if symptomatic, with follow-up as needed	Every 2 to 3 years after age 18
	Provide education about symptoms of intussusception. <sup>7</sup>	At time of diagnosis of PJS	As needed
Pancreatic	Magnetic resonance cholangiopancreatography (MRCP) with contrast or endoscopic ultrasound (EUS). <sup>1, 6, 9, 10</sup>	30 to 35 years, or 10 years younger than the earliest pancreatic cancer diagnosis in the family, whichever comes first	Annually
Female Breast	Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness. <sup>9</sup>	18 years	NA
	Clinical encounter, including clinical breast exam, ongoing risk assessment and risk-reduction counseling <sup>1, 9</sup>	25 to 30 years, or 5 to 10 years younger than the earliest age of breast cancer diagnosis in the family	Every 6 to 12 months
	Mammography and breast MRI with and without contrast <sup>1, 9</sup>	30 years	Annually
	Consider risk-reducing mastectomy. <sup>9</sup>	Individualized	NA
Gastric	Upper endoscopy <sup>1, 6, 7</sup>	Baseline at age 8 to 10 years, or earlier if symptomatic, with follow-up as needed	Every 2 to 3 years after age 18
Small Bowel	Small bowel visualization with CT, MRI enterography or video capsule endoscopy <sup>1, 6, 7</sup>	Baseline at 8 to 10 years, or earlier if symptomatic, with follow-up as needed, but no later than age 18	Every 2 to 3 years after age 18
Ovarian	Physical exam, monitor for precocious puberty <sup>7</sup>	Age 8	Annually

CANCER TYPE	PROCEDURE	AGE TO BEGIN	FREQUENCY (UNLESS OTHERWISE INDICATED BY FINDINGS)
	Pelvic examination with consideration of pelvic ultrasound <sup>1</sup>	18 to 20 years	Annually
Lung	Provide education about symptoms and smoking cessation. <sup>1</sup>	As needed	As needed
Cervical	Consider total hysterectomy (including uterus and cervix). <sup>1</sup>	After completion of childbearing	NA
	Pelvic examination and pap smear <sup>1</sup>	18 to 20 years	Annually
Endometrial	Pelvic examination with endometrial biopsy if abnormal bleeding <sup>1</sup>	18 to 20 years	Annually
Testicular	Physical and testicular examination and observation for feminizing changes. <sup>1,7</sup>	Age 10	Annually

## Information for Family Members

The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the *STK11* gene.

This patient's relatives are at risk for carrying the same mutation(s) and associated cancer risks as this patient. Cancer risks for females and males who have this/these mutation(s) are provided below.

Family members should talk to a healthcare provider about genetic testing. Close relatives such as parents, children, brothers and sisters have the highest chance of having the same mutation(s) as this patient. Other more distant relatives such as cousins, aunts, uncles, and grandparents also have a chance of carrying the same mutation(s). Testing of at-risk relatives can identify those family members with the same mutation(s) who may benefit from surveillance and early intervention.

Since *STK11* mutations carry a risk for complications in children and some screenings are recommended to begin by age 8, consideration should be given to the possibility of mutation testing in childhood.

There are reports of cases where individuals with a mutation in *STK11* have not inherited the mutation from a parent. In these cases the mutation has developed spontaneously in that individual (a de novo mutation). Once this occurs, the children of that individual are each at 50% risk of inheriting the mutation.<sup>2</sup>

## References

1. Gupta S, et al. NCCN Clinical Practice Guidelines in Oncology® Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. V 4.2024. Apr 2. Available at <https://www.nccn.org>.
2. McGarrity TJ, et al. Peutz-Jeghers Syndrome. 2021 Sep 2. In: Adam MP, et al., editors. GeneReviews® [Internet]. PMID: 20301443.
3. van Lier MG, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010 105:1258-64. PMID: 20051941.
4. Beggs AD, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010 59:975-86. PMID: 20581245.
5. Banno K, et al. Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review). Oncol Lett. 2013 6:1184-1188. PMID: 24179492.
6. Boland CR, et al. Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2022 162(7):2063-2085. PMID: 35487791.
7. MacFarland SP, et al. Pediatric Cancer Screening in Hereditary Gastrointestinal Cancer Risk Syndromes: An Update from the AACR Childhood Cancer Predisposition Working Group. Clin Cancer Res. 2024 Oct 15;30(20):4566-4571. PMID: 39190470.
8. SEER\*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. [Cited 2025 Apr 1]. Available from <https://seer.cancer.gov/explorer/>.
9. Daly M et al. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V 3.2025. Mar 6. Available at <https://www.nccn.org>.

10. Goggins M, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. *Gut*. 2020 69:7-17. PMID: 31672839.

Last Updated on 03-Jun-2025